XG046

XG046 is an experimental drug candidate being developed by Xgene Pharmaceutical for the treatment of pain. It is currently in the discovery stage and is part of the company's "Pain Discovery Program." While specific details regarding its molecular targets and modality have not been publicly disclosed, Xgene's broader research platform is focused on the development of dual-targeting prodrugs. These molecules are designed to chemically combine two therapeutic agents—typically a cyclooxygenase (COX) inhibitor and a gabapentinoid targeting the α2δ subunit of voltage-gated calcium channels—into a single molecule to provide synergistic pain relief with improved safety and pharmacokinetic profiles.